These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23829374)

  • 41. Antibacterial activities and characterization of novel inhibitors of LpxC.
    Clements JM; Coignard F; Johnson I; Chandler S; Palan S; Waller A; Wijkmans J; Hunter MG
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1793-9. PubMed ID: 12019092
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Complete Pathway Model for Lipid A Biosynthesis in Escherichia coli.
    Emiola A; George J; Andrews SS
    PLoS One; 2014; 10(4):e0121216. PubMed ID: 25919634
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives.
    Niu Z; Lei P; Wang Y; Wang J; Yang J; Zhang J
    Eur J Med Chem; 2023 May; 253():115326. PubMed ID: 37023679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. LpxC (UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase) inhibitors: A long path explored for potent drug design.
    Kumar Pal S; Kumar S
    Int J Biol Macromol; 2023 Apr; 234():122960. PubMed ID: 36565833
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of Novel Inhibitors of LpxC Displaying Potent in Vitro Activity against Gram-Negative Bacteria.
    Surivet JP; Panchaud P; Specklin JL; Diethelm S; Blumstein AC; Gauvin JC; Jacob L; Masse F; Mathieu G; Mirre A; Schmitt C; Lange R; Tidten-Luksch N; Gnerre C; Seeland S; Herrmann C; Seiler P; Enderlin-Paput M; Mac Sweeney A; Wicki M; Hubschwerlen C; Ritz D; Rueedi G
    J Med Chem; 2020 Jan; 63(1):66-87. PubMed ID: 31804826
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis, biological evaluation, and molecular docking studies of deoxygenated C-glycosides as LpxC inhibitors.
    Dreger A; Hoff K; Agoglitta O; Bülbül EF; Melesina J; Sippl W; Holl R
    Bioorg Chem; 2021 Dec; 117():105403. PubMed ID: 34758434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insights into the Zinc-Dependent Deacetylase LpxC: Biochemical Properties and Inhibitor Design.
    Kalinin DV; Holl R
    Curr Top Med Chem; 2016; 16(21):2379-430. PubMed ID: 27072691
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria.
    Yethon JA; Whitfield C
    Curr Drug Targets Infect Disord; 2001 Aug; 1(2):91-106. PubMed ID: 12455407
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure, inhibition, and regulation of essential lipid A enzymes.
    Zhou P; Zhao J
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Nov; 1862(11):1424-1438. PubMed ID: 27940308
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    Purnapatre KP; Rao M; Pandya M; Khanna A; Chaira T; Bambal R; Upadhyay DJ; Masuda N
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437618
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxC.
    Barb AW; Leavy TM; Robins LI; Guan Z; Six DA; Zhou P; Hangauer MJ; Bertozzi CR; Raetz CR
    Biochemistry; 2009 Apr; 48(14):3068-77. PubMed ID: 19256534
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential strategies for the eradication of multidrug-resistant Gram-negative bacterial infections.
    Huwaitat R; McCloskey AP; Gilmore BF; Laverty G
    Future Microbiol; 2016 Jul; 11():955-72. PubMed ID: 27357521
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural and Biological Basis of Small Molecule Inhibition of
    Ma X; Prathapam R; Wartchow C; Chie-Leon B; Ho CM; De Vicente J; Han W; Li M; Lu Y; Ramurthy S; Shia S; Steffek M; Uehara T
    ACS Infect Dis; 2020 Jun; 6(6):1480-1489. PubMed ID: 31402665
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enzymatic synthesis of lipid A molecules with four amide-linked acyl chains. LpxA acyltransferases selective for an analog of UDP-N-acetylglucosamine in which an amine replaces the 3"-hydroxyl group.
    Sweet CR; Williams AH; Karbarz MJ; Werts C; Kalb SR; Cotter RJ; Raetz CR
    J Biol Chem; 2004 Jun; 279(24):25411-9. PubMed ID: 15044493
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.
    McAllister LA; Montgomery JI; Abramite JA; Reilly U; Brown MF; Chen JM; Barham RA; Che Y; Chung SW; Menard CA; Mitton-Fry M; Mullins LM; Noe MC; O'Donnell JP; Oliver RM; Penzien JB; Plummer M; Price LM; Shanmugasundaram V; Tomaras AP; Uccello DP
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6832-8. PubMed ID: 23046961
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure and reactivity of LpxD, the N-acyltransferase of lipid A biosynthesis.
    Buetow L; Smith TK; Dawson A; Fyffe S; Hunter WN
    Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4321-6. PubMed ID: 17360522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure of the bacterial deacetylase LpxC bound to the nucleotide reaction product reveals mechanisms of oxyanion stabilization and proton transfer.
    Clayton GM; Klein DJ; Rickert KW; Patel SB; Kornienko M; Zugay-Murphy J; Reid JC; Tummala S; Sharma S; Singh SB; Miesel L; Lumb KJ; Soisson SM
    J Biol Chem; 2013 Nov; 288(47):34073-34080. PubMed ID: 24108127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
    Furuya T; Shapiro AB; Comita-Prevoir J; Kuenstner EJ; Zhang J; Ribe SD; Chen A; Hines D; Moussa SH; Carter NM; Sylvester MA; Romero JAC; Vega CV; Sacco MD; Chen Y; O'Donnell JP; Durand-Reville TF; Miller AA; Tommasi RA
    Bioorg Med Chem; 2020 Dec; 28(24):115826. PubMed ID: 33160146
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acyl chain preference and inhibitor identification of Moraxella catarrhalis LpxA: Insight through crystal structure and computational studies.
    Pratap S; Kesari P; Yadav R; Dev A; Narwal M; Kumar P
    Int J Biol Macromol; 2017 Mar; 96():759-765. PubMed ID: 28057571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Recent progress in development of antibiotics against Gram-negative bacteria].
    Xu ZQ; Xu ZY
    Yao Xue Xue Bao; 2013 Jul; 48(7):993-1004. PubMed ID: 24133966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.